Laser vaccine adjuvant for cutaneous immunization

Expert Review of Vaccines

Volumn 10, Issue 10, 2011, Pages 1397-1403

  Chen, Xinyuan ^a   Wu, Mei X ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

adjuvant; cell motility; cutaneous vaccination; laser; noninflammation

Indexed keywords

ALUMINUM DERIVATIVE; ANTIGEN; ANTISENSE OLIGONUCLEOTIDE; AS 04; GAMMA INTERFERON; HEPATITIS B VACCINE; IMIQUIMOD; INFLUENZA VACCINE; INTERLEUKIN 4; MALARIA VACCINE; MIFAMURTIDE; NICOTINE VACCINE; PHOSPHORYL LIPID A; QS 21; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BIOAVAILABILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG FORMULATION; GENE TARGETING; HUMAN; HUMORAL IMMUNITY; ILLUMINATION; IMMUNE RESPONSE; IMMUNIZATION; INJECTION SITE REACTION; LANGERHANS CELL; LASER; LASER VACCINE ADJUVANT; LEUKOCYTE MIGRATION; LYMPH NODE; MACROPHAGE; MALARIA; MICROINJECTION; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROCONVERSION; SKIN SCAR;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; INJECTIONS, INTRADERMAL; LASERS; MICE; MICE, INBRED BALB C; SKIN; VACCINES;

EID: 80053948560     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.112     Document Type: Article

References (48)

1. Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25(52), 8833-8842 (2007).
2. Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 7, 13 (2009).
3. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650-658 (2008).
4. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26(26), 3197-3208 (2008).
5. Chen X, Kim P, Farinelli B et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS One 5(10), e13776 (2010).
6. Lofquist JM, Weimert NA, Hayney MS. Smallpox: a review of clinical disease and vaccination. Am. J. Health Syst. Pharm. 60(8), 749-756 (2003).
7. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351(22), 2286-2294 (2004).
8. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351(22), 2295-2301 (2004).
9. Van Damme P, Arnou R, Kafeja F et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect. Dis. 10, 134 (2010).
10. Mikszta JA, Sullivan VJ, Dean C et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191(2), 278-288 (2005).
11. Mikszta JA, Dekker JP III, Harvey NG et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74(12), 6806-6810 (2006).
12. Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin. Infect. Dis. 14(3), 697-707 (1992).
13. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 254(22), 3203-3206 (1985).
14. Warrell MJ, Warrell DA, Suntharasamai P et al. An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis. Lancet 2(8345), 301-304 (1983).
15. Barraclough KA, Wiggins KJ, Hawley CM et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am. J. Kidney Dis. 54(1), 95-103 (2009).
16. Jackson LA, Austin G, Chen RT et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19(32), 4703-4709 (2001).
17. Frech SA, Dupont HL, Bourgeois AL et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a Phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371(9629), 2019-2025 (2008).
18. Matriano JA, Cormier M, Johnson J et al. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 19(1), 63-70 (2002).
19. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369-393 (2009).
20. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin. Infect. Dis. 50(10), 1331-1338 (2010).
21. Wack A, Rappuoli R. Vaccinology at the beginning of the 21st Century. Curr. Opin. Immunol. 17(4), 411-418 (2005).
22. Lin K, Doolan K, Hung CF, Wu TC. Perspectives for preventive and therapeutic HPV vaccines. J. Formos. Med. Assoc. 109(1), 4-24 (2010).
23. Asa PB, Wilson RB, Garry RF. Antibodies to squalene in recipients of anthrax vaccine. Exp. Mol. Pathol. 73(1), 19-27 (2002).
24. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp. Mol. Pathol. 68(1), 55-64 (2000).
25. Satoh M, Kuroda Y, Yoshida H et al. Induction of lupus autoantibodies by adjuvants. J. Autoimmun. 21(1), 1-9 (2003).
26. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5(7), 505-517 (2007).
27. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831), 1628-1632 (2007).
28. Gu M, Hine PM, James JW, Giri L, Nabors GS. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 25(3), 526-534 (2007).
29. Fransen F, Boog CJ, van Putten JP, van der LP. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect. Immun. 75(12), 5939-5946 (2007).
30. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun. 71(5), 2498-2507 (2003).
31. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23-32 (2009).
32. Onikienko SB, Zemlyanoy AB, Margulis BA et al. Interactions of bacterial endotoxins and lipophilic xenobiotics with receptors associated with innate immunity. Donosologiya (St Petersburg) 1, 32-54 (2006).
33. Nishibu A, Ward BR, Jester JV, Ploegh HL, Boes M, Takashima A. Behavioral responses of epidermal Langerhans cells in situ to local pathological stimuli. J. Invest. Dermatol. 126(4), 787-796 (2006).
34. Sangaletti S, Gioiosa L, Guiducci C et al. Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. J. Cell Sci. 118(Pt 16), 3685-3694 (2005).
35. Pflicke H, Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J. Exp. Med. 206(13), 2925-2935 (2009).
36. Doukas AG, Kollias N. Transdermal drug delivery with a pressure wave. Adv. Drug Deliv. Rev. 56(5), 559-579 (2004).
37. Lee WR, Shen SC, Liu CR, Fang CL, Hu CH, Fang JY. Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: an animal study. J. Control Release 115(3), 344-353 (2006).
38. Zeira E, Manevitch A, Manevitch Z et al. Femtosecond laser: a new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization. FASEB J. 21(13), 3522-3533 (2007).
39. Ng CP, Hinz B, Swartz MA. Interstitial fluid flow induces myofibroblast differentiation and collagen alignment in vitro. J. Cell Sci. 118(Pt 20), 4731-4739 (2005).
40. Ostberg JR, Kabingu E, Repasky EA. Thermal regulation of dendritic cell activation and migration from skin explants. Int. J. Hyperthermia 19(5), 520-533 (2003).
41. Klas SD, Petrie CR, Warwood SJ et al. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine 26(43), 5494-5502 (2008).
42. Gupta RK. New advances in vaccine technologies and applications. 13-15 February 1995, Bethesda, Maryland, USA. Vaccine 13(16), 1623-1625 (1995).
43. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13(14), 1263-1276 (1995).
44. Alving CR, Detrick B, Richards RL, Lewis MG, Shafferman A, Eddy GA. Novel adjuvant strategies for experimental malaria and AIDS vaccines. Ann. NY Acad. Sci. 690, 265-275 (1993).
45. Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359(24), 2521-2532 (2008).
46. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336(2), 86-91 (1997).
47. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? J. Autoimmun. 14(1), 1-10 (2000).
48. Waisbren BA Sr. Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complimentarity in the presence of an immunologic adjuvant and specific HLA patterns. Med. Hypotheses 70(2), 346-348 (2008).